<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="iso-abbrev">Signal Transduct Target Ther</journal-id><journal-title-group><journal-title>Signal Transduction and Targeted Therapy</journal-title></journal-title-group><issn pub-type="ppub">2095-9907</issn><issn pub-type="epub">2059-3635</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7506210</article-id><article-id pub-id-type="publisher-id">318</article-id><article-id pub-id-type="doi">10.1038/s41392-020-00318-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xiang</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Xiaoqian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lili</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Zhengsen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Shijun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Ruiying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanbai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ying</surname><given-names>Tianlei</given-names></name><address><email>tlying@fudan.edu.cn</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8283-7135</contrib-id><name><surname>Jiang</surname><given-names>Shibo</given-names></name><address><email>shibojiang@fudan.edu.cn</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.274504.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4530</institution-id><institution>College of Life Sciences, </institution><institution>Hebei Agricultural University, </institution></institution-wrap>Baoding, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.274504.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4530</institution-id><institution>Research Center of Chinese Jujube, </institution><institution>Hebei Agricultural University, </institution></institution-wrap>Baoding, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, China </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>9</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>9</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>5</volume><elocation-id>212</elocation-id><history><date date-type="received"><day>9</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>28</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Drug discovery</kwd><kwd>Microbiology</kwd><kwd>Drug discovery</kwd><kwd>Microbiology</kwd><kwd>Drug discovery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>82041025</award-id><award-id>81630090</award-id><principal-award-recipient><name><surname>Jiang</surname><given-names>Shibo</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>a starting grant from Hebei Agricultural University(YJ201843).</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Coronaviruses represent a large family of viruses common in human and many different species of animals, including camels, cattle, cats, and bats. However, only a few of these viruses infect people and cause disease. The 2019 novel coronavirus (SARS-CoV-2), which causes Coronavirus disease 2019 (COVID-19), is the seventh known coronavirus to infect humans. The other 6 coronaviruses (HCoVs) are HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-associated coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV). SARS-CoV and MERS-CoV cause very severe symptoms, while the other four viruses usually cause only mild to moderate upper respiratory disease in humans.</p><p id="Par3">Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by SARS-CoV, the first worldwide pandemic caused by a coronavirus. Before it was contained, SARS had affected 32 countries in North America, South America, Europe, and Asia. As of December 31, 2003, the total number of SARS cases worldwide had reached 8096, with 774 deaths and a fatality rate of about 9.6% (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/">https://www.who.int/csr/sars/country/table2004_04_21/en/</ext-link>). COVID-19 refers to the respiratory symptoms and pneumonia caused by SARS-CoV-2 infection. By Sep 18, 2020, according to WHO, SARS-CoV-2 had resulted in 30,369,778 confirmed cases and 948,795 deaths worldwide (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>). The total number of COVID-19 cases may, however, be higher owing to the inherent difficulties in identifying and counting mild and asymptomatic cases. In addition, the capacity to detect COVID-19 remains inadequate. Some characteristics of SARS-CoV and SARS-CoV-2 are compared in this review (Table <xref rid="Tab1" ref-type="table">1</xref>). We also provide statistics on the distribution of these two epidemics in countries around the world (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of SARS-CoV and SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>SARS-CoV</th><th>SARS-CoV-2</th></tr></thead><tbody><tr><td>Species</td><td>&#x003b2; Coronavirus, beta-CoV, lineage B</td><td>&#x003b2; Coronavirus, beta-CoV, lineage B</td></tr><tr><td>Origin</td><td>Bat</td><td>Bat</td></tr><tr><td>Intermediate hosts</td><td>Not known</td><td><italic>Manis pentadactyla</italic><sup><xref ref-type="bibr" rid="CR68">68</xref></sup></td></tr><tr><td>Genetic material</td><td>Positive-stranded RNA</td><td>Positive-stranded RNA</td></tr><tr><td>Receptor</td><td>Angiotensin-converting enzyme 2 (ACE2)</td><td>Angiotensin-converting enzyme 2 (ACE2)</td></tr><tr><td>Route of transmission</td><td>Respiratory droplets, close contact, fecal-oral route (?)</td><td>Respiratory droplets, close contact, fecal-oral route (?)</td></tr><tr><td>Incubation period</td><td>5 (2&#x02013;10) days (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/postoutbreak/en/">https://www.who.int/csr/sars/postoutbreak/en/</ext-link>)</td><td>5.2 (1.8&#x02013;12.4) days<sup><xref ref-type="bibr" rid="CR69">69</xref></sup></td></tr><tr><td>Clinical symptoms</td><td>Fever (99%), Documented elevated temperature (85%), Nonproductive cough (69%), Myalgia (49%), Dyspnea (42%)<sup><xref ref-type="bibr" rid="CR70">70</xref></sup></td><td>Fever (83%), Cough (82%), Shortness of breath (31%), Muscle ache (11%), Confusion (9%), Headache (8%), Sore throat (5%), Rhinorrhoea (4%), Chest pain (2%), Diarrhea (2%), Nausea and vomiting (1%)<sup><xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td>Fatality rate</td><td>9.6%</td><td>~3.1%<sup>a</sup></td></tr><tr><td>Epidemic area</td><td>Asia, Europe, North, and South America</td><td>Globally</td></tr><tr><td>Epidemic time</td><td>~8 months</td><td>Unknown</td></tr><tr><td>High-risk for severe illness</td><td>Young and middle-aged</td><td>Elderly or frail with underlying disease</td></tr><tr><td>Possibility of recurrence</td><td>Very unlikely</td><td>Very likely</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Calculated based on the total number of the confirmed cases and deaths as of Sep 19, 2020</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Statistical charts of cumulative cases. Statistical charts of cumulative number of SARS cases (<bold>a</bold>) and COVID-19 cases (<bold>b</bold>)</p></caption><graphic xlink:href="41392_2020_318_Fig1_HTML" id="d30e527"/></fig></p><p id="Par4">Treating with small-molecule compounds has shown good clinical effect, but we still need to be mindful of side effects which play an important role in the selection of therapeutic methods and reagents. Currently, no specific drugs can completely cure the disease caused by SARS-CoV-2. Therefore, it is urgent to develop safe and effective therapeutic reagents. Fortunately, human antibodies can accurately and efficiently identify antigens, and they have few side effects in humans. Antibody drugs are widely used in many fields, including cancer and infectious diseases. In addition, antibodies against SARS-CoV and MERS-CoV have been extensively developed.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup></p></sec><sec id="Sec2"><title>Structure and function of the RBD in SARS-CoV and SARS-CoV-2 spike protein</title><p id="Par5">Coronaviruses are enveloped spherical particles, the spike glycoproteins (S protein) of which form a crown-like surface (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). The S protein consists of two subunits: S1 and S2 (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). The fragment located in the middle of the S1 subunit (amino acids (aa) 318&#x02013;510) is the minimum receptor-binding domain (RBD) in SARS-CoV, which binds to the host cell receptor angiotensin-converting enzyme 2 (ACE2).<sup><xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref></sup> The binding of RBD and ACE2 triggers the conformational change of the S2 subunit and virus particle invasion<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The crystal structure of the RBD bound to ACE2 peptidase indicates that RBD presents a flat concave surface at the N-terminus of the receptor peptidase on which aa 445&#x02013;460 anchor the entire receptor-binding loop of the RBD core.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> This loop (aa 424&#x02013;494) makes complete contact with the ACE2 receptor and is called the receptor binding motif (RBM)<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). Scientists have already developed safe and effective vaccine candidates against SARS-CoV based on the RBD and screened neutralizing antibodies using it as an antigen. These studies indicate that the RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses, making the RBD an important target for the development of vaccines and immunotherapeutics.<sup><xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref></sup> Since the emergence of SARS-CoV, researchers have screened, or designed, many NMAbs targeting the RBD. Following the outbreak of COVID-19, the sequence of SARS-CoV-2 was soon identified, and it was found that the structure and function of its RBD are very similar to those of SARS-CoV. Moreover, the cell receptor for both viruses is ACE2,<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup> and the crystal structure of both virus RBDs interacting with ACE2 is shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Therefore, some NMAbs targeting SARS-CoV RBD may also have potential neutralizing activity against SARS-CoV-2. This means that researchers can use the SARS-CoV-2 RBD to screen for NMAbs and design vaccines against SARS-CoV-2. Most recently, Yang et al have reported that a SARS-CoV-2 RBD-based recombinant COVID-19 vaccine could induce potent neutralizing antibody responses in the immunized mice, rabbits, and NHPs, and provided protection in non-human primates (NHPs) against SARS-CoV-2 challenge,<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> highlighting the importance of the RBD in development of neutralizing antibodies and vaccines.<fig id="Fig2"><label>Fig. 2</label><caption><p>Schematic diagram of coronavirus particle and S protein gene partitioning. (<bold>a</bold>) Major structural proteins of the coronavirus particle include Spike glycoprotein (S protein); Membrane (M) protein; Nucleocapsid (N) protein; and Envelope (E) protein. (<bold>b</bold>) The S protein is mainly divided into S1 and S2 subunits and subdivided again into signal peptide (SP); N-terminal domain (NTD); receptor-binding domain (RBD), which contains receptor binding motif (RBM); fusion peptide (FP); heptad repeat region 1 (HR1); heptad repeat region 2 (HR2); transmembrane region (TM); and cytoplasmic tail (CP) according to different functions</p></caption><graphic xlink:href="41392_2020_318_Fig2_HTML" id="d30e606"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Schematic diagram of coronavirus life cycle. The virion enters the cell through recognizing specific receptor, uses the host cell resources to carry on genome replication and synthesis of major structural proteins, and then finally assembles into the mature virion which is then released out of cell. The invasion process mainly includes (<bold>a</bold>) coronavirus S protein recognition and binding to cell receptors, along with virus attachment to the cell; (<bold>b</bold>) induction of conformational changes in the S protein upon binding, in which the fusion protein is exposed and inserted into the host cell membrane; (<bold>c</bold>) HR1 and HR2 of the S2 subunit gradually approaching each other, narrowing the distance between viral envelope and host cell membrane; (<bold>d</bold>, <bold>e</bold>) HR1 and HR2 forming a six helical bundle (6-HB), which causes the virus envelope and host cell membrane to fuse from the hemifusion state to complete fusion, thus releasing the virus gene into the host. Viral genes replicate and translate within cells to produce genomic RNA and viral proteins, which are assembled with the proteins to form viral particles</p></caption><graphic xlink:href="41392_2020_318_Fig3_HTML" id="d30e630"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Crystal structure of RBD binding to ACE2. (<bold>a</bold>) RBD (gray) of SARS-CoV specifically binds the receptor ACE2 (dark green) (PDB: 2AJF), and the interface is marked purple; (<bold>b</bold>) RBD (gray) of SARS-CoV-2 specifically binds the receptor ACE2 (PDB: 6LZG), and the interface is marked hot pink</p></caption><graphic xlink:href="41392_2020_318_Fig4_HTML" id="d30e645"/></fig></p><sec id="Sec3"><title>RBD-specific human NMAbs against SARS-CoV</title><p id="Par6">NMAbs targeting SARS-CoV RBD generally prevent the attachment of the virus to the host cell by interfering with the binding of viral RBD to cellular ACE2 receptor (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). These RBD-targeted NMAbs can be roughly divided into the following three categories based on their different binding sites on RBD. First, NMAbs that bind to the ACE2-binding site on RBD, including the receptor-binding motif (RBM), can functionally mimic ACE2 to bind RBD and block ACE2-RBD binding (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). Second, NMAbs that bind to the epitope outside or partly overlap ACE2-binding site on RBD can indirectly block ACE2-RBD binding without functionally mimicking ACE2 to bind RBD (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). Third, NMAbs that bind to the epitope outside ACE2-binding site on RBD and could not block ACE2-RBD binding (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Pattern of NMAbs action. The major types of neutralizing monoclonal antibodies (NMAbs) include immunoglobulin G (IgG), single-stranded variable region fragments (scFvs), heavy-chain antibody (HcAb) and single-domain antibodies (sdAbs). NMAbs exert antiviral activity by (<bold>a</bold>) NMAbs functionally mimicking ACE2 to bind RBD and blocking ACE2-RBD binding; (<bold>b</bold>) NMAbs binding RBD without functionally mimicking ACE2 but blocking ACE2-RBD binding; (<bold>c</bold>) NMAbs binding RBD but without blocking ACE2-RBD binding (interface is marked pink)</p></caption><graphic xlink:href="41392_2020_318_Fig5_HTML" id="d30e680"/></fig></p></sec><sec id="Sec4"><title>NMAbs functionally mimicking ACE2 to bind RBD and blocking ACE2-RBD binding</title><p id="Par7">In the development of antibodies against SARS-CoV, eight (6A, 8C, 12E, 26H, 27D, 80R, 91M, and 92N) recombinant human single chain variable fragments (scFvs) targeting the S1 of SARS-CoV S glycoprotein were identified from two nonimmune phage libraries of human antibodies.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> One of them, 80R, effectively neutralized SARS-CoV (Urbani strain) in vitro. 80R scFv competes with soluble ACE2 to bind the RBD in the S1 domain (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>) with high affinity (equilibrium dissociation constant Kd =&#x02009;32.3&#x02009;nM). At a concentration of 7.43&#x02009;nM, 80R scFv can neutralize &#x0003e;50% of the testing wells from SARS-CoV infection. In most cases, the bivalent full-length immunoglobulin is more effective than its corresponding scFv because of avidity, effector functions, and prolonged serum half-life. The same neutralizing activity was achieved by 80R IgG1 at a concentration as low as 0.37&#x02009;nM. Moreover, 80R IgG1 inhibits syncytial formation between cells expressing S protein and cells expressing ACE2.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> In a further study, 80R IgG1 could efficiently protect mice from SARS-CoV infection, noting that the core of its target is aa 324 to 503 in the S protein of SARS-CoV.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> This is also the first effective antibody against SARS-CoV screened from an antibody library.<fig id="Fig6"><label>Fig. 6</label><caption><p>Crystal structure of NMAb binding to RBD. (<bold>a</bold>) 80&#x02009;R (light green) imitates ACE2 binding to the interface (purple) on RBD of SARS-CoV (PDB: 7BZ5); (<bold>b</bold>) m396 (orange) binds to RBD of SARS-CoV without functionally mimicking ACE2, preventing RBD from binding to ACE2 (PDB: 2DD8). (<bold>c</bold>) CB6 (sky blue) functionally mimics ACE2 binding to the interface (hot pink) on RBD of SARS-CoV-2 (PDB: 7C01); (<bold>d</bold>) S309 (grass green) binds to RBD of SARS-CoV-2 without blocking the binding of RBD to ACE2 (PDB: 6WPS). (<bold>e</bold>) The SARS-CoV-specific NMAb CR3022 (purple) binds to RBD of SARS-CoV-2 without blocking the binding of RBD of SARS-CoV-2 to ACE2 (PDB: 6W41)</p></caption><graphic xlink:href="41392_2020_318_Fig6_HTML" id="d30e724"/></fig></p><p id="Par8">CR3014 was also identified from semisynthetic antibody phage display libraries. The results showed that CR3014 targets residues 318 to 510, a region previously identified as the SARS-CoV RBD. Furthermore, complete protection against 100 TCID<sub>50</sub> (50% tissue culture infectious dose) of SARS-CoV infectivity was achieved at 42&#x02009;nM of CR3014 IgG.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> At the same time, researchers aligned residues 318&#x02013;510 of the S protein from 114 human SARS-CoV isolates published in GenBank.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> The results showed that eight sequences of the S protein were different from those used in the beginning of this article. These sequences were expressed in the form of recombinant S318&#x02013;510 fragments. Among them, CR3014 had no neutralizing effect on the N479 mutant sequence, indicating that this residue is very important for the binding of CR3014.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> In a follow-up study, CR3014 IgG suppressed replication of SARS-CoV in the lungs of infected ferrets, attenuated SARS-CoV-induced visible lung lesions, and eliminated virus reproduction in the pharyngeal region at 10&#x02009;mg/kg.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup></p><p id="Par9">To study the inactivated virus as a potential vaccine, inactivated SARS-CoV particles were used as the immunogen to induce humoral and/or cell-mediated immune response in mice, and antibodies were detected in the hybridoma supernatant. Two NMAbs (1A5, 2C5) with strong neutralizing effects on SARS-CoV were screened out. The results of virus neutralization experiments showed that 1A5 (32&#x02009;&#x000b5;g/&#x000b5;l) and 2C5 (14&#x02009;&#x000b5;g/&#x000b5;l) were diluted 45,000 and 11,000 times to achieve IC<sub>50</sub> values of ~0.71&#x02009;&#x000b5;g/ml and 1.27&#x02009;&#x000b5;g/ml, respectively. When mapping epitopes of NMAbs on specific domains of S protein, both NMAbs were found to target residues 310&#x02013;535 in S protein of SARS-CoV.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup></p><p id="Par10">By imitating the human immune response to SARS-CoV, S230.15 was identified by B cell-based Epstein-Barr virus (EBV) transformation and used the RBD of S protein as antigen. S230.15 competes with SARS-CoV receptor ACE2 to bind to the RBD of the S protein. S230.15 potently inhibited viral entry into cells and cell fusion mediated by the S protein of SARS-CoV in vitro. Furthermore, the antiviral activity of S230.15 was tested in mice infected with recombinant SARS-CoV. Mice infected with Urbani and GD03 were treated with 200&#x02009;&#x000b5;g of S230.15, and the mice were completely protected.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup></p></sec><sec id="Sec5"><title>NMAbs binding RBD without functionally mimicking ACE2 but blocking ACE2-RBD binding</title><p id="Par11">As mentioned before, m396 was identified from healthy human antibody libraries of volunteers by using the RBD of SARS-CoV S protein as antigen.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> Further study showed that m396 by targeting the RBD (Fig. <xref rid="Fig6" ref-type="fig">6b</xref>), m396 could neutralize GD03 and Tor2 viruses with IC<sub>50</sub> of 0.1&#x02009;&#x000b5;g/ml and 0.01&#x02009;&#x000b5;g/ml, respectively, and neutralize pseudoviruses from the Urbani isolate. Mice infected with Urbani and GD03 were treated with 200&#x02009;&#x000b5;g m396, and the mice were completely protected. Meanwhile, m396 showed significant, but incomplete, protection against SZ16 infection in mice. By analyzing the key residues of m396 on RBD of SARS-CoV, Zhu et al found that the epitope of m396 overlapped the binding site of ACE2, including residues Y484, T486, T487, G488, Y491.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> Therefore, m396 neutralizes viruses by competing with ACE2 to bind to RBD.</p><p id="Par12">In addition to the humanization of mouse antibodies, transgenic technology can replace the mouse immunoglobulin gene with human immunoglobulin gene, and animal immunization with antigen can obtain full human antibodies. Following this practice, a fully human antibody, 201, was developed, that targets residues 490&#x02013;510 of the SARS-CoV S protein. Affinity measurements showed an affinity Kd of 34&#x02009;nM between monoclonal antibodies (mAbs) and soluble S<sub>590</sub> (residues 1&#x02013;590 of the SARS-CoV S protein fragment consisting of residues 1&#x02013;590). The NMAb 201 specifically blocked binding of S<sub>590</sub> to Vero E6 cells in a flow cytometry &#x02013;based assay and. 201 provided a 50% maximal protective effect at concentrations of ~1&#x02009;nM in the neutralization assays against SARS-CoV in vitro. The NMAb 201 completely protected mice against SARS-CoV infection at a concentration of 40&#x02009;mg/kg. In doses as low as 1.6&#x02009;mg/kg, mice could be effectively protected, even though replication of virus was not completely inhibited in the lungs.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup></p><p id="Par13">NMAbs were produced from mice immunized with inactivated SARS-CoV (Tor-3 strain, isolated from a patient infected in the Toronto SARS outbreak<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>) using the hybridoma technique. The most potent mAbs, including F26G9, F26G10, F26G18, and F26G19, were screened out in ELISA assays.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> These mAbs were then humanized and tested for their affinity and neutralization activity to SARS-CoV. Results showed that chimeric F26G18 bound full-length S protein (rFS) with a Kd of 1.78&#x02009;&#x000b1;&#x02009;0.63&#x02009;nM and that chimeric F26G18 had a neutralization titer of 2.47&#x02009;nM which matched that of parental F26G18 with a neutralization titer of 2.07&#x02009;nM against heat inactivated Tor2.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> Also, ELISA assays were performed to determine S-protein and RBD specificity for the different mAbs. Of these mAbs, chimeric F26G18 bound to the SARS-CoV RBD, and the reaction was independent of glycosylation. Furthermore, F26G18 and its chimera mapped to a discrete sequential epitope (<sub>460</sub>FSPDGKPCTPPALNCYW<sub>476</sub>), which overlaps the ACE2 binding site, in the RBD of SARS-CoV S protein,<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> suggesting that F26G18 neutralizes SARS-CoV infection by blocking RBD-ACE2 the binding.</p><p id="Par14">Using hybridoma technology, 26 hybridomas were screened out from mice immunized with radiation-inactivated SARS-CoV. Nine of the most representative clones were selected for further identification. The results showed that five (154C, 240C, 341C, 534C, 560C) of these clones targeted the S protein and that NMAb 341C recognized residues 490&#x02013;510 in the SARS-CoV S protein. Furthermore, the results of neutralization experiments showed that 341C had the strongest neutralizing activity, completely inhibiting the lysis of virus-infected Vero E6 cells at a dilution of 1: 1280.<sup><xref ref-type="bibr" rid="CR24">24</xref></sup></p><p id="Par15">In a recent study, five variable heavy homodimers (VHH) (VHH-1, VHH-6, VHH-35, VHH-44, and VHH-72) were screened out from a llama immunized with the S protein of SARS-CoV. To assess the antiviral activity of these mAbs, neutralization assays were performed in vitro using SARS-CoV Urbani S pseudotyped lentiviruses. The results showed that VHH-72 neutralized the pseudovirus with an IC<sub>50</sub> value of 0.14&#x02009;&#x000b5;g/ml. Epitope mapping showed that VHH-72 targets the RBD of SARS-CoV S protein, and the crystal structure shows that VHH-72 blocks the binding of ACE2 and RBD through steric hindrance.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></p></sec><sec id="Sec6"><title>NMAbs binding RBD but without blocking ACE2-RBD binding</title><p id="Par16">The genome of SARS-CoV continues to mutate during replication, and many virus subtypes already exist. Therefore, the targets of antibodies need to extensively cover different SARS-CoV isolates and control potential neutralization escape mutations for effective human immune prophylaxis. Combinations of neutralizing and noncompetitive mAbs may have these properties.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup></p><p id="Par17">The previously mentioned CR3014 IgG does not work in all SARS-CoV strains. In order to cover the remaining virus strains, CR3022 was identified from an immune scFv phage display library constructed from the lymphocytes of a convalescent SARS patient from Singapore. According to the study, all CR3014 IgG escaped virus showed a single point mutation at amino acid position 462 (proline to leucine, P462L) in the S protein. CR3022 IgG does not compete with CR3014 in combination with recombinant S1 fragments. CR3022 IgG completely neutralized the SARS-CoV strain HKU-39849 and the CR3014 IgG escape variants at a concentration of 23.5&#x02009;&#x000b5;g/ml. The synergistic effect of CR3014 IgG and CR3022 IgG may also reduce the total antibody dose of passive immunity against SARS-CoV infection.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup></p><p id="Par18">Transgenic H2L2 mice, which encode chimeric immunoglobulin, including variable regions of human heavy and light chains and constant regions of rats, were immunized with the S protein of SARS-CoV. Four hybridomas that activated on the S protein of SARS-CoV were identified. Among them, the chimeric antibody 47D11 showed neutralization activity to SARS-CoV pseudovirus. 47D11 was then reconstructed and expressed in the form of human IgG1 and further identified. The results showed that the humanized antibody 47D11 could bind the SARS-CoV S protein expressed on the cell surface and inhibit the infection of SARS-CoV pseudovirus with an IC<sub>50</sub> value of 0.061&#x02009;&#x003bc;g/ml. Infection of Vero E6 cells with SARS-CoV was neutralized with an IC<sub>50</sub> value of 0.19&#x02009;&#x003bc;g/ml. 47D11 was shown to target the RBD of SARS-CoV in an ELISA assay.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup></p><p id="Par19">NMAb S309 was identified from the peripheral blood of SARS- infected patients. Neutralization assays showed that antibody S309 could effectively neutralize pseudoviruses carrying the S proteins of SARS-CoV isolates from the early, middle and late phases of the 2002&#x02013;2003 epidemic with IC<sub>50</sub> values between 120 and 180&#x02009;ng/ml. S309 targets the front end of the RBD of the SARS-CoV S protein.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup></p></sec><sec id="Sec7"><title>RBD-specific human NMAbs against SARS-CoV-2</title><p id="Par20">Since SARS-CoV-2 and SARS-CoV share the receptor ACE2 and their RBDs have similar sequences, the NMAbs against SARS-CoV-2 can be classified in the same way as those against SARS-CoV (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).</p></sec><sec id="Sec8"><title>NMAbs functionally mimicking ACE2 to bind RBD and blocking ACE2-RBD binding</title><p id="Par21">Five (1E2, 2F2, 3F11, 4D8, and 5F8) single-domain antibodies (sdAbs) with antiviral activity to SARS-CoV-2 in vitro were identified from a fully synthetic, humanized phage display library with recombinant RBD of the SARS-CoV-2 S protein. In a pseudotyped virus neutralization assay, monomeric sdAb 3F11 showed neutralization activity with an IC<sub>50</sub> of 0.0038&#x02009;&#x000b5;g/ml. 3F11 also neutralized SARS-CoV-2 with an IC<sub>50</sub> value of 0.4360&#x02009;&#x000b5;g/ml in a live virus neutralization assay. The results of a competitive ligand-binding assay suggested that 3F11 completely blocked the binding between SARS-CoV-2 RBD and ACE2.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> To overcome the limitations of monovalent sdAbs,<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> sdAbs was fused with human IgG1 Fc fragments. Results showed that the neutralization activity of recombinant 3F11 significantly increased by 10.8-fold in molar concentration with an IC<sub>50</sub> value of 0.0020&#x02009;&#x000b5;g/ml in a SARS-CoV-2 pseudotyped virus entry assay.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup></p><p id="Par22">Fourteen effective NMAbs against SARS-CoV-2 were identified from 60 convalescent patients using high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells. Among them, BD-368-2 had the most potency, effectively neutralizing the pseudovirus of SARS-CoV-2 and live SARS-CoV-2 with an IC<sub>50</sub> of 1.2&#x02009;ng/ml and 15&#x02009;ng/ml, respectively. In SARS-CoV-2-infected transgenic mice, BD-368-2 also showed strong therapeutic and prophylactic effects. In addition, the target verification results showed that the epitopes of BD-368-2 overlapped with the ACE2 binding site, and the crystallographic analysis indicates that BD23-Fab blocks the interaction between RBD and ACE2.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup></p><p id="Par23">In addition, ab1 was identified from eight large phage displayed Fab, scFv and VH libraries by panning against the RBD of the SARS-CoV-2 S protein. ab1 competes with hACE2 (human ACE2) for binding to RBD, indicating that ab1 neutralizes SARS-CoV-2 infection by blocking RBD-ACE2 binding. The ab1 IgG1 could completely neutralize SARS-CoV-2 in a concentration of &#x0003c;400&#x02009;ng/ml. Moreover, it protected transgenic mice expressing hACE2 from a high-titer intranasal SARS-CoV-2 challenge. A relatively low number of somatic mutations occurred in the sequence of ab1, as determined by sequence alignment results. This indicates that either natural SARS-CoV-2 infection or RBD-based vaccines could stimulate the quick production of ab1-like antibodies. The ab1 IgG1 showed no safety deficiencies; therefore, it has therapeutic and prophylactic potential for SARS-CoV-2 infections.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup></p><p id="Par24">Recently, CB6 was identified from the PBMCs of a COVID-19 convalescent patient by using recombinant RBD of the SARS-CoV-2 S protein. CB6 binds RBD (Fig. <xref rid="Fig6" ref-type="fig">6c</xref>) and blocks the binding of soluble SARS-CoV-2-RBD with hACE2. Both pseudovirus and live virus neutralization assays were performed to investigate the neutralization activity of CB6 against SARS-CoV-2 in vitro. The results showed that CB6 could inhibit the pseudovirus of SARS-CoV-2 with ND<sub>50</sub> (50% neutralization dose) values of 0.036, 0.023 and 0.041&#x02009;&#x003bc;g/ml in Huh7, Calu-3, and HEK293T cells, respectively. CB6 could also effectively neutralize SARS-CoV-2 with an ND<sub>50</sub> of 0.036&#x02009;&#x000b1;&#x02009;0.007&#x02009;&#x003bc;g/ml in infected Vero E6 cells. Furthermore, CB6 was tested in a rhesus macaque model infected with SARS-CoV-2 in both prophylactic and treatment settings and showed a considerable effect. Investigating the neutralization mechanism showed that CB6 could block the binding of hACE2 to RBD through steric hindrance and competition with interface residues.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup></p><p id="Par25">Similarly, two NMAbs, B38 and H4, were isolated from a convalescent COVID-19 patient in China and were recently reported to have antiviral activity against SARS-CoV-2. Similar to Cao et al.,<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> the RBD of SARS-CoV-2 was used as bait to isolate specific single memory B cells from PBMC of the patient. In order to identify the antiviral activity of these isolated mAbs, a virus neutralization experiment against SARS-CoV-2 (BetaCoV/Shenzhen/SZTH-003/2020) was performed. The results showed that B38 had higher potency to inhibit viral infection with an IC<sub>50</sub> value of 0.177&#x02009;&#x003bc;g/ml. This was followed by H4, which inhibited viral infection with an IC<sub>50</sub> value of 0.896&#x02009;&#x003bc;g/ml. The crystal structure of the RBD-B38 complex shows that most of the residues on the B38 binding epitope overlap with the RBD-ACE2 binding interface, suggesting that B38 neutralizes SARS-CoV-2 infection by functionally mimicking ACE2 to bind RBD and block the RBD-ACE2 binding. B38 and H4 competed with ACE2 for RBD binding in the competition assay. In animal trials, lung viral load was reduced by 32.8% and 26% with a single dose of 25&#x02009;mg/kg of B38 and H4, respectively, compared with the untreated group. Similarly, a competition assay was performed to identify whether B38 and H4 act on the same epitope on the RBD. No competition was observed between B38 and H4, suggesting that the two NMAbs acted on different RBD sites. Therefore, B38 and H4 can be used as an ideal mAb pair for virus targeting to avoid immune escape in future clinical applications.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup></p></sec><sec id="Sec9"><title>NMAbs binding RBD without functionally mimicking ACE2 but blocking ACE2-RBD binding</title><p id="Par26">Similarly, another NMAb, 7B11, was identified from previously screened antibodies. It is specific to SARS-CoV. ELISA assays were performed to detect the binding activity against the RBD of SARS-CoV-2, and the results showed that six mAbs (46C1, 13B6, 29H4, S29, 7B11, and 18F3) had cross-reactivity against SARS-CoV-2 RBD. 7B11 showed cross-neutralization activity against SARS-CoV-2 in a pseudovirus neutralization assay, neutralizing about 80% of pseudovirus at 10&#x02009;&#x003bc;g/ml. According to this report, 7B11 could block the binding of SARS-CoV and SARS-CoV-2 RBDs to ACE2 owing to proximity between target and binding site.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup></p><p id="Par27">In order to rapidly obtain human NMAbs targeting SARS-CoV-2, 206 mAbs specific to the RBD of SARS-CoV-2 S protein were screened from the blood of eight SARS-CoV-2-infected individuals. Analysis of 13 of the 69 antibodies from patient two showed neutralization activity of P2C-1F11 and P2B-2F6 against the SARS-CoV-2 pseudovirus with IC<sub>50</sub> values of 0.03 and 0.05&#x02009;&#x000b5;g/ml, respectively. Consistent with experimental results of the pseudovirus neutralization, P2C-1F11 and P2B-2F6 neutralization of SARS-CoV-2 demonstrated the most potent neutralization activity with IC<sub>50</sub> values of 0.03 and 0.41&#x02009;&#x003bc;g/ml, respectively.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup></p><p id="Par28">A competitive biopanning strategy was developed to effectively screen RBD blocking antibodies from the phage display antibody library. rRBD-15 and rRBD-16, with the highest affinity for RBD screened from competitive biopanning, were expressed as a full-length IgG1. They can bind to the RBD with EC<sub>50</sub> values at 3.8&#x02009;nM and 5.3&#x02009;nM, respectively in vitro. Only rRBD-15 inhibited the binding of RBD to ACE2 with an IC<sub>50</sub> at 3.0&#x02009;nM, while rRBD-16 had no blocking or neutralizing activity. In a pseudovirus neutralization assay, rRBD-15 showed potent neutralization activity against SARS-CoV-2 pseudovirus infection with an IC<sub>50</sub> of 12.2 nM.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup></p><p id="Par29">VHH-72 has been shown to have cross-reactivity between SARS-CoV and SARS-CoV-2 S protein. Experimental data showed that the binding affinity of VHH-72 to the SARS-CoV-2 RBD was ~39&#x02009;nM, which was weaker than that of the SARS-CoV RBD. According to the report, this was related to the rapid dissociation of VHH-72. Among the amino acid residues of RBD binding to VHH-72, the only mutation found was Arg426, which is Asn439 in the SARS-CoV-2 RBD. However, the binding of VHH-72 to RBD of SARS-CoV-2 could not be detected in ELISA assays, and VHH-72 could not neutralize SARS-CoV-2 pseudovirus. In order to overcome the rapid dissociation of VHH-72, scientists modified VHH-72, including a tail-to-head fusion of two VHH-72 molecules connected by a (GGGGS)3 linker (VHH-72-VHH-72) and a genetic fusion of VHH-72 to the Fc domain of human IgG1 (VHH-72-Fc). Both variants exhibited binding ability to the S proteins of SARS-CoV and SARS-CoV-2, and VHH-72-Fc neutralized SARS-CoV-2 pseudovirus with an IC<sub>50</sub> of ~0.2&#x02009;&#x000b5;g/ml.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></p><p id="Par30">To investigate the implications of a SARS-CoV-2 RBD-hACE2 interaction, Chen et al.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> first identified the inhibitory activity of plasma from recovered patients and then sorted out the memory B cells of positive plasma samples. Using reverse transcription polymerase chain reaction, they next cloned the VH and VL of IgG which were expressed in vitro again, finally obtaining three mAbs (311mab&#x02013;31B5, 311mab&#x02013;32D4 and 311mab&#x02013;31B9). Consistent with plasma test results, 311mab-31B5 and 311mab-32D4 could efficiently block the SARS-CoV-2 RBD-hACE2 interaction with an IC<sub>50</sub> of 0.0332 and 0.0450&#x02009;&#x003bc;g/ml, respectively, while 311mab&#x02013;31B9 had no inhibitory activity against this interaction. Both 311mab-31B5 and 311mab-32D4 showed neutralizing activity against SARS-CoV-2 pseudovirus with an IC<sub>50</sub> of 0.0338 and 0.0698&#x02009;&#x003bc;g/ml, respectively, while 311mab-31B9 had no neutralization activity in this assay.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup></p><p id="Par31">In another study,<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> common mAbs were screened out from convalescent patients and specific mAbs were obtained using high-throughput screening with specific antigen. A neutralization assay for the pseudovirus of SARS-CoV-2 and a protection assay in Syrian hamsters were performed to examine the antiviral activity of mAbs. Among the identified mAbs, CC12.1 effectively neutralized the pseudovirus of SARS-CoV-2 with an IC<sub>50</sub> value of 0.019&#x02009;&#x000b5;g/ml and live SARS-CoV-2 with an IC<sub>50</sub> value of 0.022&#x02009;&#x000b5;g/ml. CC12.1 could completely protect Syrian hamsters against the Washington strain USA-WA1/2020 (BEI Resources NR-52281) in a plasma concentration of 22&#x02009;&#x000b5;g/ml. Furthermore, CC12.1 was found to target the RBD of SARS-CoV-2 and block ACE2 binding in a mapping assay. In addition, CC6.29 and CC6.30, which target the RBD of SARS-CoV-2, have the highest potency against SARS-CoV-2 pseudovirus with IC<sub>50</sub> values of 2&#x02009;ng/ml and 1&#x02009;ng/ml, respectively.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup></p><p id="Par32">Similarly, COVA1-18 and COVA2-15 were identified from convalescent patients by using SARS-CoV-2 S protein as antigen. Both NMAbs targeted the RBD of SARS-CoV-2 S protein.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> These mAbs showed neutralization activity against the pseudovirus of SARS-CoV-2 with an IC<sub>50</sub> value of 8&#x02009;ng/ml and potently inhibited live SARS-CoV-2 infection with IC<sub>50</sub> values of 7 and 9&#x02009;ng/ml, respectively.</p><p id="Par33">To obtain a broad-spectrum vaccine that effectively targets known and potential human coronaviruses, eight NMAbs with SARS-CoV-2 cross-neutralizing activity were identified by using a memory B cell repertoire from a convalescent SARS donor. It is worth noting that these NMAbs can effectively cross-neutralize SARS-CoV, SARS-CoV-2 and the bat SARS-like virus WIV1. ADI-55689 binds to the edge of the ACE2 binding site, close to the more conservative core region of the RBD structure, while ADI-56046 binds to the flexible tip of RBD. The IgG format of these NMAbs showed neutralizing activity against SARS-CoV-2 live virus at 100&#x02009;nM, and similar results were shown in a VSV-based pseudovirus neutralizing assay. In a MLV-based pseudovirus neutralizing assay, ADI-55689 and ADI-56046 showed neutralizing activity with IC<sub>50</sub> values of 0.05&#x02013;1.4&#x02009;&#x003bc;g/ml and 0.004&#x02013;0.06&#x02009;&#x003bc;g/ml against SARS-CoV-2 and SARS-CoV respectively. Similar IC<sub>50</sub> values were observed in SARS-CoV-2 and SARS-CoV live virus neutralization assays.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup></p><p id="Par34">Using transgenic mice and PBMC of SARS-CoV-2-infected patients, a large number of single B cells that produced antibodies which specifically bind to SARS-CoV-2-RBD were screened out. The antibody genes of these B cells were then sequenced, and then expressed as complete antibodies. Finally, about 40 antibodies with unique sequences and neutralizing activity against SARS-CoV-2 pseudoviruses were obtained. Among of them, nine (REGN10989, REGN10987, REGN10933, REGN10934, REGN10977, REGN10964, REGN10954, REGN10984, REGN10986) of the most potent antibodies were identified in subsequent assays. Their IC<sub>50</sub> values range from 7&#x02013;99 pM. These antibodies can effectively block the binding of ACE2 to the RBD. In addition, four (REGN10989, REGN10987, REGN10933, REGN10934) of them can effectively neutralize the virus with IC<sub>50</sub> values of 7.38, 42.1, 37.4, 28.3 pM, respectively. REGN10933 and REGN10987 can simultaneously bind to distinct regions of the RBD through crystal structure analysis. Therefore, these two NMAbs can be used as cocktails to exert antiviral activity against SARS-CoV-2. Human trials (clinicaltrials.gov NCT04426695 and NCT04425629) of an antibody cocktail are being tested now.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> In addition, these antibodies were combined to explore their effect on escape mutations. The results showed that this noncompetitive antibody cocktail therapy can effectively avoid viral escape mutations.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup></p><p id="Par35">A single-domain antibody H11 that specifically binds to SARS-CoV-2 RBD was identified by screening a naive llama phage display antibody library. Through random mutation, two mutants H11-H4 and H11-D4 H11 that have higher affinity for SARS-CoV-2 RBD were obtained. Bivalent Fc-nanobody fusion, H11-H4-Fc, and H11-D4-Fc, compete with ACE2 for RBD binding and H11-H4 and H11-D4 recognize the same epitope, which partly overlaps to the ACE2 binding region in the SARS-CoV-2 RBD. H11-H4-Fc and H11-D4-Fc can block the binding of RBD to MDCK-ACE2 with IC<sub>50</sub> of 61&#x02009;nM for H11-H4-Fc, and 161&#x02009;nM for H11-D4-Fc, respectively. The results from the plaque reduction neutralization assay showed that H11-H4-Fc and H11-D4-Fc could neutralize live SARS-CoV-2 infection with the ND<sub>50</sub> of 6&#x02009;nM and 18&#x02009;nM, respectively. Combining CR3022 with H11-H4-Fc or H11-D4-Fc exhibited synergistic effect on their neutralization effect.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup></p><p id="Par36">As the pandemic continues, more and more NMAbs have been screened out. A humanized NMAb H014 was identified from a phage display antibody library generated from RNAs extracted from peripheral lymphocytes of mice immunized with SARS-CoV RBD, which could cross-neutralize SARS-CoV and SARS-CoV-2. Both IgG and Fab forms of H014 could effectively bind to the RBD of SARS-CoV and SARS-CoV-2 at sub-nM levels. H014 IgG could effectively neutralize SARS-CoV-2 and SARS-CoV pseudovirus infection with IC<sub>50</sub> of 3 and 1&#x02009;nM respectively, and can neutralize the authentic SARS-CoV-2 virus with an IC<sub>50</sub> of 38&#x02009;nM. H014 IgG could effectively protect hACE2-Tg mice from the challenge with SARS-CoV-2. H014 IgG bound to the epitope outside RBM on RBD of SARS-CoV-2, thus, preventing RBD-ACE2 binding through steric hindrance.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup></p><p id="Par37">From the lymphocytes of SARS-CoV-2 convalescent patients in Wuhan, some NMAbs were identified from the screening with SARS-CoV-2 S protein.<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> The IC<sub>50</sub> of these NMAbs against SARS-CoV-2 strain WA1/2020 in a range of 15&#x02013;4000&#x02009;ng/ml as measured with focus reduction neutralization test. Among of them, COV2-2196 and COV2-2130 could also neutralize SARS-CoV-2 pseudovirus infection. They could completely block the binding between SARS-CoV-2 RBD and hACE2 in a competition assay, but bound to different epitopes on RBD. Therefore, COV2-2196 and COV2-2130 could simultaneously bind to S protein and exhibited synergistic neutralization effect on live SARS-CoV-2 infection. The use of COV2-2196 and COV2-2130 alone or in combination could protect BALB/c mice from challenge with a mouse-adapted SARS-CoV-2. Use of COV2-2196 or COV2-2381 alone could also protect NHPs from SARS-CoV-2 infection.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup></p><p id="Par38">Ho and colleagues isolated 61 NMAbs from PBMCs of five severe COVID-19 patients. Nine of them have IC<sub>50</sub> in a range 0.7 ~ 9&#x02009;ng/ml against live SARS-CoV-2 infection. Among of them, 2&#x02013;15, 2&#x02013;7, 1&#x02013;57, and 1&#x02013;20 targeted RBD, and 2&#x02013;17, 5&#x02013;24, and 4&#x02013;8 targeted NTD, while 2&#x02013;43 and 2&#x02013;51 targeted a quaternary epitope on the top of RBD on the S protein trimer. The most potent NMAb 2&#x02013;15 could neutralize pseudotyped and live SARS-CoV-2 infection with IC<sub>50</sub> of 5&#x02009;ng/ml and 0.7&#x02009;ng/ml, respectively, by binding RBD, competitively with ACE2. The NMAb 2&#x02013;15 could effectively protect a golden Syrian hamster model against SARS-CoV-2 infection.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup></p></sec><sec id="Sec10"><title>NMAbs binding RBD but without blocking ACE2-RBD binding</title><p id="Par39">As described in Wang et al.,<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> transgenic mice were immunized with S protein of SARS-CoV, and NMAbs that have cross-reactivity against SARS-CoV-2 were identified. Among them, the chimeric antibody 47D11 was reconstructed, expressed in the form of human IgG1, and further characterized. The results showed that the humanized 47D11 could bind SARS-CoV-2 S protein expressed on the cell surface and inhibit the infection of SARS-CoV-2 pseudovirus with an IC<sub>50</sub> value of 0.061&#x02009;&#x003bc;g/ml. Infection of Vero E6 cells with SARS-CoV-2 was neutralized with an IC<sub>50</sub> value of 0.57&#x02009;&#x003bc;g/ml. 47D11 was shown to target the RBD of the SARS-CoV-2 S protein in an ELISA assay.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup></p><p id="Par40">18F3 was screened out from antibodies specific to SARS-CoV. ELISA assays were performed to detect the activity of binding to the RBD of SARS-CoV-2, and the results showed that six mAbs (46C1, 13B6, 29H4, S29, 7B11, and 18F3) had cross-reactivity against SARS-CoV-2 RBD. 18F3 showed cross-neutralization activity against SARS-CoV-2 in the pseudovirus neutralization assay, neutralizing about 80% of pseudovirus at 10&#x02009;&#x003bc;g/ml. However, 18F3 could not block the binding of SARS-CoV and SARS-CoV-2 RBDs to ACE2 owing to the distance between target and binding site.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup></p><p id="Par41">As mentioned earlier, fully human antibodies have an advantage as drugs in human. In addition to camel origin and humanized sdAbs, fully human sdAbs have been reported.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> In this study, the S1 fragment was used as an antigen to screen sdAbs that specifically bound to the antigen from a fully human phage display library, followed by pseudovirus and live virus neutralization experiments, and a competition assay against ACE2, on the most representative antibodies. Among these sdAbs, results showed that the most potent antibody, n3130, could neutralize &#x0003e;90% SARS-CoV-2 pseudovirus at a concentration of 10&#x02009;&#x000b5;g/ml, while n3088 could neutralize ~80% pseudovirus at a concentration of 10&#x02009;&#x000b5;g/ml. No cytopathic effect (CPE) was observed in n3130 and only minimal signs of CPE were observed in n3088, while significant levels of CPE were detected in other antibody groups. However, none of these antibodies could effectively compete with ACE2 in binding the RBD of SARS-CoV-2 S protein.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup></p><p id="Par42">Based on the similarity of S protein between SARS-CoV-2 and SARS-CoV, researchers attempted to identify NMAbs with cross-reactivity for SARS-CoV-2 from the peripheral blood of SARS-infected patients. In order to detect the cross-reactivity of NMAbs against SARS-CoV-2, pseudovirus neutralization assays with a murine leukemia virus (MLV) pseudotyping system were performed. Results showed that S309 could effectively neutralize both pseudoviruses. By targeting the RBD (Fig. <xref rid="Fig6" ref-type="fig">6d</xref>), S309 potently neutralized authentic SARS-CoV-2 (2019n-CoV/USA_WA1/2020) with an IC<sub>50</sub> of 79&#x02009;ng/ml, via recognition of a highly conserved epitope in the S domain, comprising the N343-glycan.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup></p></sec><sec id="Sec11"><title>RBD-specific cross-neutralizing MAbs against SARS-CoV and SARS-CoV-2</title><p id="Par43">As discussed previously, some NMAbs can cross-bind the RBD of SARS-CoV and SARS-CoV-2, and some have cross-neutralization activity. The S protein sequence and crystal structure of SARS-CoV were found to be highly similar to those of SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref></sup> Therefore, an affinity test of SARS-CoV NMAbs CR3022 and others was performed against the RBD of SARS-CoV-2. The results showed that only CR3022 had high affinity for the RBD of SARS-CoV-2,<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> but it did not block binding of ACE2 to SARS-CoV-2 RBD (Fig. <xref rid="Fig6" ref-type="fig">6e</xref>). However, the authors of this study note that multiple antibodies have been reported that offer in vivo protection, even without in vitro neutralization activity.<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> On the contrary, recent research results by scientists have shown that CR3022 has neutralizing activity against SARS-CoV-2 with IC<sub>50</sub> of ~0.114&#x02009;&#x003bc;g/ml in vitro.<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> NMAbs 47D11, 18F3, VHH-72 and S309 derived from SARS-CoV have cross-neutralization activity to SARS-CoV-2 because they target highly conserved sites between SARS-CoV and SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> Recently, a series of cross-antibodies were screened out from memory B cell repertoire of a convalescent SARS donor.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup></p></sec></sec><sec id="Sec12"><title>Conclusion and prospects</title><p id="Par44">Whether coronaviruses, such as SARS-CoV and MERS-CoV, will threaten human health in the future is unknown. With the third pandemic of coronavirus pneumonia caused by SARS-CoV-2, this reminds us that the answer may be in the affirmative. Therefore, we need to develop prophylactic and therapeutic drugs against coronavirus infection as soon as possible. Antibody drugs with the characteristics of precise targeting, few side effects and significant curative effect are good choices for the treatment of coronavirus infection, and the RBD is the most important therapeutic target.</p><p id="Par45">In this article, we have summarized NMAbs that target the RBD of SARS-CoV and SARS-CoV-2 and may have prophylactic or therapeutic potency against SARS and COVID-19. The sources, antiviral activity and targets of NMAbs are compared in Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>. A body of evidence suggests that antibodies targeting conserved sites have more broad-spectrum antiviral activity. Therefore, antibodies that target conserved sites are more likely to become broad-spectrum antibodies for coronaviruses that have already appeared or will appear in the future. From these studies, we understand that the antiviral ability of a single NMAb is limited, but that the combination of multiple NMAbs (cocktails) that target different epitopes can achieve satisfactory results in a synergistic way, limiting the possibility of virus escape. The recently reported NMAb 4A8, isolated from convalescent patients and targets N-terminal domain of SARS-CoV-2 S protein, has neutralizing activity against pseudoviruses with EC<sub>50</sub> of 49&#x02009;&#x003bc;g/ml and live viruses with EC<sub>50</sub> of 0.61&#x02009;&#x003bc;g/ml respectively,<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> and could be used as a candidate of a cocktail. Indeed, therapeutic antibody cocktails have been used successfully for the treatment of patients infected with Ebola virus.<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> Among NMAbs we discussed, there are some NMAbs whose sequences are remarkable closed to germline antibodies (e.g., ab1, 2&#x02013;15),<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup> without extensive somatic hypermutations. This bodes well for vaccine development, and these NMAbs have more potency for therapy.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Neutralizing monoclonal antibodies against SARS-CoV</p></caption><table frame="hsides" rules="groups"><thead><tr><th>NMAb&#x02019;s name</th><th>Type</th><th>Source</th><th>Preparation</th><th>Target</th><th>Assay and result</th><th>Ref.</th></tr></thead><tbody><tr><td rowspan="2">80R</td><td rowspan="2">sdAb</td><td rowspan="2">Human</td><td rowspan="2">Nonimmune phage libraries of human antibodies</td><td rowspan="2">324&#x02013;503</td><td>LV neutralization: IC<sub>50</sub>&#x02009;&#x0003c;&#x02009;7.43&#x02009;nM;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup></td></tr><tr><td>Full protection of mice: 4/4 mice with &#x0003e;4&#x02009;log reduction in lung viral load at 12.5&#x02009;mg/kg.</td></tr><tr><td rowspan="2">CR3014</td><td rowspan="2">scFv</td><td rowspan="2">Human</td><td rowspan="2">Semisynthetic antibody phage display libraries</td><td rowspan="2">318&#x02013;510</td><td>LV neutralization: ND<sub>100</sub> at 42&#x02009;nM;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup></td></tr><tr><td>Protection of ferrets: 10&#x02009;mg/kg.</td></tr><tr><td rowspan="2"><p>1A5</p><p>2C5</p></td><td rowspan="2">IgG</td><td rowspan="2">Mouse</td><td rowspan="2">Animal immunization; hybridoma technology</td><td rowspan="2">310&#x02013;535</td><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.71&#x02009;&#x000b5;g/ml.</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR17">17</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;1.27&#x02009;&#x000b5;g/ml.</td></tr><tr><td>S230.15</td><td>IgG</td><td>Human</td><td>B cell-based EBV transformation</td><td>RBD</td><td>Full protection of mice: 200&#x02009;&#x003bc;g/mouse.</td><td><sup><xref ref-type="bibr" rid="CR18">18</xref></sup></td></tr><tr><td rowspan="3">m396</td><td rowspan="3">IgG1</td><td rowspan="3">Human</td><td rowspan="3">Healthy human antibody libraries of volunteers</td><td rowspan="3">482&#x02013;491</td><td>LV (GD03) neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.1&#x02009;&#x000b5;g/ml;</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR18">18</xref></sup></td></tr><tr><td>LV (Tor2) neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.01&#x02009;&#x000b5;g/ml;</td></tr><tr><td>Full protection of mice: 200&#x02009;&#x003bc;g/mouse.</td></tr><tr><td rowspan="2">201</td><td rowspan="2">IgG1</td><td rowspan="2">Human</td><td rowspan="2"><p>Transgenic mice;</p><p>hybridoma technology</p></td><td rowspan="2">490&#x02013;510</td><td>LV neutralization: IC<sub>50</sub>&#x02009;&#x0223c;&#x02009;1&#x02009;nM;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR20">20</xref></sup></td></tr><tr><td>Full protection of mice: 40&#x02009;mg/kg.</td></tr><tr><td>chimeric F26G18</td><td>IgG</td><td>Chimeric antibody</td><td>Animal immunization; hybridoma technology</td><td>460&#x02013;476</td><td>LV neutralization: titer&#x02009;=&#x02009;2.07&#x02009;nM.</td><td><sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup></td></tr><tr><td>341&#x02009;C</td><td>IgG</td><td>Mouse</td><td>Animal immunization; hybridoma technology</td><td>490&#x02013;510</td><td>LV neutralization: ND<sub>100</sub> at a dilution of 1:1280.</td><td><sup><xref ref-type="bibr" rid="CR24">24</xref></sup></td></tr><tr><td>VHH-72</td><td>sdAb</td><td>llama</td><td>Animal immunization and sequencing</td><td>RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.14&#x02009;&#x000b5;g/ml.</td><td><sup><xref ref-type="bibr" rid="CR25">25</xref></sup></td></tr><tr><td>CR3022</td><td>scFv</td><td>Human</td><td>Semisynthetic antibody phage display libraries</td><td>RBD</td><td>LV neutralization: IC<sub>100</sub>&#x02009;=&#x02009;23.5&#x02009;&#x000b5;g/ml.</td><td><sup><xref ref-type="bibr" rid="CR26">26</xref></sup></td></tr><tr><td rowspan="2">47D11</td><td rowspan="2">IgG</td><td rowspan="2">Chimeric antibody</td><td rowspan="2"><p>Transgenic mice;</p><p>hybridoma technology</p></td><td rowspan="2">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.061&#x02009;&#x003bc;g/ml;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR27">27</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.19&#x02009;&#x003bc;g/ml.</td></tr><tr><td>S309</td><td>IgG</td><td>human</td><td>Peripheral blood of SARS-infected patients</td><td>the front end of RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;120&#x02009;~&#x02009;180&#x02009;ng/ml.</td><td><sup><xref ref-type="bibr" rid="CR28">28</xref></sup></td></tr><tr><td>ADI-55689</td><td rowspan="8">IgG</td><td rowspan="8">Human</td><td rowspan="8">Memory B cell repertoire of a convalescent SARS donor</td><td rowspan="8">RBD</td><td rowspan="8">PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.004&#x02009;~&#x02009;0.06&#x02009;&#x003bc;g/ml.</td><td rowspan="8"><sup><xref ref-type="bibr" rid="CR41">41</xref></sup></td></tr><tr><td>ADI-55993</td></tr><tr><td>ADI-56000</td></tr><tr><td>ADI-55688</td></tr><tr><td>ADI-56046</td></tr><tr><td>ADI-56010</td></tr><tr><td>ADI-55690</td></tr><tr><td>ADI-55951</td></tr></tbody></table><table-wrap-foot><p><italic>PsV</italic> pseudovirus, <italic>LV</italic> live virus</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Neutralizing monoclonal antibodies against SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>NMAbs&#x02019;s name</th><th>Type</th><th>Source</th><th>Preparation</th><th>Target</th><th>Assay and result</th><th>Ref.</th></tr></thead><tbody><tr><td rowspan="2">3F11</td><td rowspan="2">sdAb</td><td rowspan="2">Human</td><td rowspan="2">Humanized phage display library</td><td rowspan="2">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;3.8&#x02009;ng/ml;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR29">29</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;436&#x02009;ng/ml.</td></tr><tr><td rowspan="3">BD-368-2</td><td rowspan="3">IgG</td><td rowspan="3">Human</td><td rowspan="3">B cells of convalescent patients; Single cell sequencing</td><td rowspan="3">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;1.2&#x02009;ng/ml;</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR31">31</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;15&#x02009;ng/ml;</td></tr><tr><td>Full protection of mice: 20&#x02009;mg/kg.</td></tr><tr><td rowspan="3">ab1</td><td rowspan="3">IgG</td><td rowspan="3">Human</td><td rowspan="3">Phage displayed Fab, scFv and VH libraries</td><td rowspan="3">RBD</td><td>Reporter Gene neutralization assay: 200&#x02009;ng/ml;</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR32">32</xref></sup></td></tr><tr><td>LV neutralization: ND<sub>100</sub>&#x02009;&#x0003c;&#x02009;400&#x02009;ng/ml;</td></tr><tr><td>Full protection of mice: 0.3&#x02009;mg of IgG1 ab1.</td></tr><tr><td rowspan="3">CB6</td><td rowspan="3">IgG</td><td rowspan="3">Human</td><td rowspan="3">B cells of convalescent patients</td><td rowspan="3">RBD</td><td>PsV neutralization: ND<sub>50</sub>&#x02009;=&#x02009;0.036&#x02009;&#x003bc;g/ml;</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR33">33</xref></sup></td></tr><tr><td>LV neutralization: ND<sub>50</sub>&#x02009;=&#x02009;0.036&#x02009;&#x003bc;g/ml;</td></tr><tr><td>Protection of rhesus macaques: 50&#x02009;mg/kg.</td></tr><tr><td rowspan="2">B38</td><td rowspan="2">IgG</td><td rowspan="2">Human</td><td rowspan="2">Peripheral blood of SARS-CoV-2- infected patients</td><td rowspan="2">RBD</td><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.177&#x02009;&#x000b5;g/ml;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR34">34</xref></sup></td></tr><tr><td>Protection of mice: Lung viral load reduced by 32.8% compared with PBS control.</td></tr><tr><td rowspan="2">H4</td><td rowspan="2">IgG</td><td rowspan="2">Human</td><td rowspan="2">Peripheral blood of SARS-CoV-2- infected patients</td><td rowspan="2">RBD</td><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.896&#x02009;&#x000b5;g/ml;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR34">34</xref></sup></td></tr><tr><td>Protection of mice: Lung viral load reduced by 26% compared with PBS control.</td></tr><tr><td rowspan="2"><p>7B11</p><p>18F3</p></td><td rowspan="2">IgG</td><td rowspan="2">Mouse</td><td rowspan="2">Animal immunization; hybridoma technology</td><td rowspan="2">RBD</td><td>PsV neutralization: IC<sub>80</sub>&#x02009;=&#x02009;10&#x02009;&#x003bc;g/ml.</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR35">35</xref></sup></td></tr><tr><td>PsV neutralization: IC<sub>80</sub>&#x02009;=&#x02009;10&#x02009;&#x003bc;g/ml.</td></tr><tr><td>P2C-1F11</td><td>IgG</td><td>Human</td><td>Plasma of convalescing patients</td><td>RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.03&#x02009;&#x000b5;g/ml.</td><td><sup><xref ref-type="bibr" rid="CR36">36</xref></sup></td></tr><tr><td>rRBD-15</td><td>IgG</td><td>Human</td><td>A synthetic human Fab antibody library</td><td>RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;12.2&#x02009;nM.</td><td><sup><xref ref-type="bibr" rid="CR37">37</xref></sup></td></tr><tr><td>VHH-72-Fc</td><td>HCAb</td><td>llama</td><td>Animal immunization and sequencing</td><td>RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;~&#x02009;0.2&#x02009;&#x000b5;g/ml.</td><td><sup><xref ref-type="bibr" rid="CR25">25</xref></sup></td></tr><tr><td rowspan="2"><p>311mab&#x02013;31B5</p><p>311mab&#x02013;32D4</p></td><td rowspan="2">IgG</td><td rowspan="2">Human</td><td rowspan="2">B cells of convalescent patients</td><td rowspan="2">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;33.8&#x02009;ng/ml.</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR38">38</xref></sup></td></tr><tr><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;69.8&#x02009;ng/ml.</td></tr><tr><td rowspan="3">CC12.1</td><td rowspan="3">IgG</td><td rowspan="3">Human</td><td rowspan="3">B cells of convalescent patients</td><td rowspan="3">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.019&#x02009;&#x003bc;g/ml;</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR39">39</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.022&#x02009;&#x003bc;g/ml;</td></tr><tr><td>Full protection of Syrian hamsters: Antibody serum concentration of ~22&#x02009;&#x000b5;g/ml.</td></tr><tr><td rowspan="4"><p>COVA1-18</p><p>COVA2-15</p></td><td rowspan="4">IgG</td><td rowspan="4">Human</td><td rowspan="4">B cells of convalescent patients</td><td rowspan="4">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;8&#x02009;ng/ml;</td><td rowspan="4"><sup><xref ref-type="bibr" rid="CR40">40</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;7&#x02009;ng/ml.</td></tr><tr><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;8&#x02009;ng/ml;</td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;9&#x02009;ng/ml.</td></tr><tr><td rowspan="2">47D11</td><td rowspan="2">IgG</td><td rowspan="2">Chimeric antibody</td><td rowspan="2">Transgenic mice; hybridoma technology</td><td rowspan="2">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.061&#x02009;&#x003bc;g/ml;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR27">27</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.57&#x02009;&#x003bc;g/ml.</td></tr><tr><td rowspan="2">S309</td><td rowspan="2">IgG</td><td rowspan="2">human</td><td rowspan="2">Peripheral blood of SARS-infected patients</td><td rowspan="2">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;3.5&#x02009;nM;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR28">28</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;79&#x02009;ng/ml.</td></tr><tr><td>ADI-55689</td><td rowspan="8">IgG</td><td rowspan="8">Human</td><td rowspan="8">Memory B cell repertoire of a convalescent SARS donor</td><td rowspan="8">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.05&#x02009;~&#x02009;1.4&#x02009;&#x003bc;g/ml;</td><td rowspan="8"><sup><xref ref-type="bibr" rid="CR41">41</xref></sup></td></tr><tr><td>ADI-55993</td><td>LV neutralization: showed neutralizing activity at 100&#x02009;nM.</td></tr><tr><td>ADI-56000</td><td rowspan="6"/></tr><tr><td>ADI-55688</td></tr><tr><td>ADI-56046</td></tr><tr><td>ADI-56010</td></tr><tr><td>ADI-55690</td></tr><tr><td>ADI-55951</td></tr><tr><td rowspan="8"><p>REGN10989</p><p>REGN10987</p><p>REGN10933</p><p>REGN10934</p></td><td rowspan="8">IgG</td><td rowspan="8">Human</td><td rowspan="8">Transgenic mice; Peripheral blood of SARS-CoV-2-infected patients; Next Generation Sequencing</td><td rowspan="8">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;7.23 pM;</td><td rowspan="8"><sup><xref ref-type="bibr" rid="CR42">42</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;7.38 pM.</td></tr><tr><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;40.6 pM;</td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;42.1 pM.</td></tr><tr><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;42.8 pM;</td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;37.4 pM.</td></tr><tr><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;54.4 pM;</td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;28.3 pM.</td></tr><tr><td rowspan="2"><p>H11-H4-Fc</p><p>H11-D4-Fc</p></td><td rowspan="2">HCAb</td><td rowspan="2">llama</td><td rowspan="2">Phage display library</td><td rowspan="2">RBD</td><td>LV neutralization: ND<sub>50</sub>&#x02009;=&#x02009;6&#x02009;nM.</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR44">44</xref></sup></td></tr><tr><td>LV neutralization: ND<sub>50</sub>&#x02009;=&#x02009;18&#x02009;nM.</td></tr><tr><td>H014</td><td>IgG</td><td>Chimeric antibody</td><td>Animal immunization and phage display</td><td>RBD</td><td><p>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;3&#x02009;nM;</p><p>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;38&#x02009;nM;</p><p>Protection of mice: Lung viral load reduced by about 10 ~100 folds compared with PBS control.</p></td><td><sup><xref ref-type="bibr" rid="CR45">45</xref></sup></td></tr><tr><td rowspan="4"><p>COV2-2196</p><p>COV2-2130</p></td><td rowspan="4">IgG</td><td rowspan="4">Human</td><td rowspan="4">Peripheral blood of convalescent patients</td><td rowspan="4">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.7&#x02009;ng/ml;</td><td rowspan="4"><sup><xref ref-type="bibr" rid="CR47">47</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;15&#x02009;ng/ml.</td></tr><tr><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;1.6&#x02009;ng/ml;</td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;107&#x02009;ng/ml.</td></tr><tr><td rowspan="3">2&#x02013;15</td><td rowspan="3">IgG</td><td rowspan="3">Human</td><td rowspan="3">Peripheral blood of COVID-19 patients</td><td rowspan="3">RBD</td><td>PsV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;0.7&#x02009;ng/ml;</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR48">48</xref></sup></td></tr><tr><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;5&#x02009;ng/ml;</td></tr><tr><td>Protection of hamsters: Viral RNA copy numbers and infectious virus titers in lung tissues were reduced by 4 logs or more compared with PBS control.</td></tr><tr><td>CR3022</td><td>IgG</td><td>Human</td><td>Gene cloning; Protein expression</td><td>RBD</td><td>LV neutralization: IC<sub>50</sub>&#x02009;=&#x02009;~&#x02009;0.114&#x02009;&#x003bc;g/ml.</td><td><sup><xref ref-type="bibr" rid="CR55">55</xref></sup></td></tr><tr><td rowspan="2">4A8</td><td rowspan="2">IgG</td><td rowspan="2">Human</td><td rowspan="2">Peripheral blood of convalescent patients</td><td rowspan="2">NTD</td><td>PsV neutralization: EC<sub>50</sub>&#x02009;=&#x02009;49&#x02009;&#x003bc;g/ml;</td><td rowspan="2"><sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td></tr><tr><td>LV neutralization: EC<sub>50</sub>&#x02009;=&#x02009;0.61&#x02009;&#x003bc;g/ml.</td></tr></tbody></table><table-wrap-foot><p><italic>PsV</italic> pseudovirus, <italic>LV</italic> live virus</p></table-wrap-foot></table-wrap></p><p id="Par46">The clinical prospects of fully human antibodies are obvious. Early studies mainly used EBV<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup> to immortalize B cells or fuse B cells with suitable partners to produce hybridoma.<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> With scientific technology updates, now methods mainly used to obtain human antibodies include (i) humanizing mouse mAbs,<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> (ii) screening for mAbs from phage display libraries of human antibody fragments,<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> and (iii) immunizing transgenic mice carrying human immunoglobulin gene, followed by hybridoma technology for production of mAbs.<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> In addition, screening of antibodies from patients is the most straightforward and simple method to obtain human antibodies as described above. As COVID-19 epidemic continues, more and more NMAbs have been isolated from the lymphocytes of COVID-19 patients. Although the neutralizing ability of convalescent plasma from some patients was relatively low, some NMAbs isolated from these patients had strong neutralizing activity with IC<sub>50</sub> as low as 2&#x02009;ng/ml against live SARS-CoV-2 infection,<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> suggesting that using a vaccine, once it is available, to elicit NMAbs could be an alternative approach. Although numerous antibodies blockbuster antibody drugs are already on the market, technological innovation to improve antibody production is still needed, given that huge amount of anti-SARS-CoV-2 antibodies are required for the clinical application. Interestingly, direct antibody synthesis in combination with computerized and bioinformatic approaches are being developed, substantially shortening the time required for antibody development.<sup><xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref></sup> At the same time, we look forward to new progress in the research and development of antibody drugs, the improvement in long half-life, high efficiency and miniaturization of antibody drugs, and the more economical development of antibody drugs.</p></sec></body><back><ack><title>Acknowledgements</title><p>This work was supported by grants from the National Natural Science Foundation of China (81974302, 82041025, and 81630090), a starting grant from Hebei Agricultural University (YJ201843).</p></ack><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par47">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Hillyer</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title><source>Trends Immunol.</source><year>2020</year><volume>41</volume><fpage>355</fpage><lpage>359</lpage><?supplied-pmid 32249063?><pub-id pub-id-type="pmid">32249063</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><etal/></person-group><article-title>The SARS-CoV S glycoprotein: expression and functional characterization</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2003</year><volume>312</volume><fpage>1159</fpage><lpage>1164</lpage><?supplied-pmid 14651994?><pub-id pub-id-type="pmid">14651994</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>DS</given-names></name></person-group><article-title>The secret life of ACE2 as a receptor for the SARS virus</article-title><source>Cell</source><year>2003</year><volume>115</volume><fpage>652</fpage><lpage>653</lpage><?supplied-pmid 14675530?><pub-id pub-id-type="pmid">14675530</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SK</given-names></name><etal/></person-group><article-title>A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>3197</fpage><lpage>3201</lpage><?supplied-pmid 14670965?><pub-id pub-id-type="pmid">14670965</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><etal/></person-group><article-title>The spike protein of SARS-CoV&#x02013;a target for vaccine and therapeutic development</article-title><source>Nat. Rev. Microbiol.</source><year>2009</year><volume>7</volume><fpage>226</fpage><lpage>236</lpage><?supplied-pmid 19198616?><pub-id pub-id-type="pmid">19198616</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><article-title>Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</article-title><source>Science</source><year>2005</year><volume>309</volume><fpage>1864</fpage><lpage>1868</lpage><?supplied-pmid 16166518?><pub-id pub-id-type="pmid">16166518</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies</article-title><source>J. Immunol</source><year>2005</year><volume>174</volume><fpage>4908</fpage><lpage>4915</lpage><?supplied-pmid 15814718?><pub-id pub-id-type="pmid">15814718</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Siddiqui</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2004</year><volume>325</volume><fpage>445</fpage><lpage>452</lpage><?supplied-pmid 15530413?><pub-id pub-id-type="pmid">15530413</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2004</year><volume>324</volume><fpage>773</fpage><lpage>781</lpage><?supplied-pmid 15474494?><pub-id pub-id-type="pmid">15474494</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>894</fpage><lpage>904</lpage><?supplied-pmid 32275855?><pub-id pub-id-type="pmid">32275855</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Chen, W. H., Strych, U., Hotez, P. J. &#x00026; Bottazzi, M. E. The SARS-CoV-2 Vaccine Pipeline: an Overview. <italic>Curr. Trop. Med. Rep</italic>, 1&#x02013;4 (2020).</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. <italic>Nature</italic> (2020).</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><etal/></person-group><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>Proc. Natl Acad. Sci. USA.</source><year>2004</year><volume>101</volume><fpage>2536</fpage><lpage>2541</lpage><?supplied-pmid 14983044?><pub-id pub-id-type="pmid">14983044</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>5900</fpage><lpage>5906</lpage><?supplied-pmid 15857975?><pub-id pub-id-type="pmid">15857975</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Brink</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>1635</fpage><lpage>1644</lpage><?supplied-pmid 15650189?><pub-id pub-id-type="pmid">15650189</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Meulen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>2139</fpage><lpage>2141</lpage><?supplied-pmid 15220038?><pub-id pub-id-type="pmid">15220038</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)</article-title><source>Virology</source><year>2005</year><volume>334</volume><fpage>134</fpage><lpage>143</lpage><?supplied-pmid 15749129?><pub-id pub-id-type="pmid">15749129</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>Proc. Natl Acad. Sci. USA.</source><year>2007</year><volume>104</volume><fpage>12123</fpage><lpage>12128</lpage><?supplied-pmid 17620608?><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabakaran</surname><given-names>P</given-names></name><etal/></person-group><article-title>Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>15829</fpage><lpage>15836</lpage><?supplied-pmid 16597622?><pub-id pub-id-type="pmid">16597622</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenough</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>191</volume><fpage>507</fpage><lpage>514</lpage><?supplied-pmid 15655773?><pub-id pub-id-type="pmid">15655773</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Krokhin, O. et al. Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. <italic>Mol. Cell. Proteomics</italic><bold>2</bold>, 346&#x02013;356 (2003).</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus</article-title><source>J. Virological Methods</source><year>2004</year><volume>120</volume><fpage>87</fpage><lpage>96</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology</article-title><source>mAbs</source><year>2010</year><volume>2</volume><fpage>53</fpage><lpage>66</lpage><?supplied-pmid 20168090?><pub-id pub-id-type="pmid">20168090</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripp</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins</article-title><source>J. Virological Methods</source><year>2005</year><volume>128</volume><fpage>21</fpage><lpage>28</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><etal/></person-group><article-title>Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1004</fpage><lpage>1015</lpage><?supplied-pmid 32375025?><pub-id pub-id-type="pmid">32375025</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Meulen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants</article-title><source>PLoS Med.</source><year>2006</year><volume>3</volume><fpage>e237</fpage><?supplied-pmid 16796401?><pub-id pub-id-type="pmid">16796401</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2251</fpage><?supplied-pmid 32366817?><pub-id pub-id-type="pmid">32366817</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>290</fpage><lpage>295</lpage><?supplied-pmid 32422645?><pub-id pub-id-type="pmid">32422645</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>X</given-names></name><etal/></person-group><article-title>Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by targeting spike receptor binding domain</article-title><source>Nat. Commun</source><year>2020</year><volume>11</volume><fpage>4528</fpage><?supplied-pmid 32913273?><pub-id pub-id-type="pmid">32913273</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake</article-title><source>Nucl. Med. Biol.</source><year>2015</year><volume>42</volume><fpage>695</fpage><lpage>702</lpage><?supplied-pmid 25960433?><pub-id pub-id-type="pmid">25960433</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients&#x02019; B cells</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>73</fpage><lpage>84</lpage><?supplied-pmid 32425270?><pub-id pub-id-type="pmid">32425270</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Li, W. et al. Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody. Preprint at 10.1101/2020.05.13.093088 (2020).</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>R</given-names></name><etal/></person-group><article-title>A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>120</fpage><lpage>124</lpage><?supplied-pmid 32454512?><pub-id pub-id-type="pmid">32454512</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>1274</fpage><lpage>1278</lpage><?supplied-pmid 32404477?><pub-id pub-id-type="pmid">32404477</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2</article-title><source>Antivir. Res.</source><year>2020</year><volume>179</volume><fpage>104820</fpage><?supplied-pmid 32405117?><pub-id pub-id-type="pmid">32405117</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>B</given-names></name><etal/></person-group><article-title>Human neutralizing antibodies elicited by SARS-CoV-2 infection</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>115</fpage><lpage>119</lpage><?supplied-pmid 32454513?><pub-id pub-id-type="pmid">32454513</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy</article-title><source>Antib. Therapeutics.</source><year>2020</year><volume>3</volume><fpage>95</fpage><lpage>100</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><volume>17</volume><fpage>647</fpage><lpage>649</lpage><?supplied-pmid 32313207?><pub-id pub-id-type="pmid">32313207</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>956</fpage><lpage>963</lpage><?supplied-pmid 32540903?><pub-id pub-id-type="pmid">32540903</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>PJM</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>643</fpage><lpage>650</lpage><?supplied-pmid 32540902?><pub-id pub-id-type="pmid">32540902</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wec</surname><given-names>AZ</given-names></name><etal/></person-group><article-title>Broad neutralization of SARS-related viruses by human monoclonal antibodies</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>731</fpage><lpage>736</lpage><?supplied-pmid 32540900?><pub-id pub-id-type="pmid">32540900</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1010</fpage><lpage>1014</lpage><?supplied-pmid 32540901?><pub-id pub-id-type="pmid">32540901</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1014</fpage><lpage>1018</lpage><?supplied-pmid 32540904?><pub-id pub-id-type="pmid">32540904</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2</article-title><source>Nat. Struct. Mol. Biol.</source><year>2020</year><volume>27</volume><fpage>846</fpage><lpage>854</lpage><?supplied-pmid 32661423?><pub-id pub-id-type="pmid">32661423</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1505</fpage><lpage>1509</lpage><?supplied-pmid 32703908?><pub-id pub-id-type="pmid">32703908</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zost</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein</article-title><source>Nat. Med</source><year>2020</year><volume>26</volume><fpage>1422</fpage><lpage>1427</lpage><?supplied-pmid 32651581?><pub-id pub-id-type="pmid">32651581</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zost</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>443</fpage><lpage>449</lpage><?supplied-pmid 32668443?><pub-id pub-id-type="pmid">32668443</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">32698192</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of human single-domain antibodies against SARS-CoV-2</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>891</fpage><lpage>898</lpage><?supplied-pmid 32413276?><pub-id pub-id-type="pmid">32413276</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Gui</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name></person-group><article-title>Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><fpage>e1007236</fpage><?supplied-pmid 30102747?><pub-id pub-id-type="pmid">30102747</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>265</fpage><lpage>269</lpage><?supplied-pmid 32015508?><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><etal/></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>382</fpage><lpage>385</lpage><?supplied-pmid 32065055?><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><etal/></person-group><article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>630</fpage><lpage>633</lpage><?supplied-pmid 32245784?><pub-id pub-id-type="pmid">32245784</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. <italic>Cell Host Microbe.</italic><bold>S1931&#x02013;3128</bold>, 30351&#x02013;30356 (2020).</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>X</given-names></name><etal/></person-group><article-title>A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>650</fpage><lpage>655</lpage><?supplied-pmid 32571838?><pub-id pub-id-type="pmid">32571838</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulangu</surname><given-names>S</given-names></name><etal/></person-group><article-title>A randomized, controlled trial of ebola virus disease therapeutics</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>2293</fpage><lpage>2303</lpage><?supplied-pmid 31774950?><pub-id pub-id-type="pmid">31774950</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinitz</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>G</given-names></name><name><surname>Koskimies</surname><given-names>S</given-names></name><name><surname>Makel</surname><given-names>O</given-names></name></person-group><article-title>EB virus-induced B lymphocyte cell lines producing specific antibody</article-title><source>Nature</source><year>1977</year><volume>269</volume><fpage>420</fpage><lpage>422</lpage><?supplied-pmid 198669?><pub-id pub-id-type="pmid">198669</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozbor</surname><given-names>D</given-names></name><name><surname>Roder</surname><given-names>JC</given-names></name></person-group><article-title>Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique</article-title><source>J. Immunol.</source><year>1981</year><volume>127</volume><fpage>1275</fpage><lpage>1280</lpage><?supplied-pmid 6268704?><pub-id pub-id-type="pmid">6268704</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpas</surname><given-names>A</given-names></name><name><surname>Dremucheva</surname><given-names>A</given-names></name><name><surname>Czepulkowski</surname><given-names>BH</given-names></name></person-group><article-title>A human myeloma cell line suitable for the generation of human monoclonal antibodies</article-title><source>Proc. Natl Acad. Sci. USA.</source><year>2001</year><volume>98</volume><fpage>1799</fpage><lpage>1804</lpage><?supplied-pmid 11172031?><pub-id pub-id-type="pmid">11172031</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Replacing the complementarity-determining regions in a human antibody with those from a mouse</article-title><source>Nature</source><year>1986</year><volume>321</volume><fpage>522</fpage><lpage>525</lpage><?supplied-pmid 3713831?><pub-id pub-id-type="pmid">3713831</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCafferty</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>AD</given-names></name><name><surname>Winter</surname><given-names>G</given-names></name><name><surname>Chiswell</surname><given-names>DJ</given-names></name></person-group><article-title>Phage antibodies: filamentous phage displaying antibody variable domains</article-title><source>Nature</source><year>1990</year><volume>348</volume><fpage>552</fpage><lpage>554</lpage><?supplied-pmid 2247164?><pub-id pub-id-type="pmid">2247164</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>LL</given-names></name></person-group><article-title>Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies</article-title><source>J. Immunol. Methods</source><year>1999</year><volume>231</volume><fpage>11</fpage><lpage>23</lpage><?supplied-pmid 10648924?><pub-id pub-id-type="pmid">10648924</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbiani</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>437</fpage><lpage>442</lpage><?supplied-pmid 32555388?><pub-id pub-id-type="pmid">32555388</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Desautels, T. et al. Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing. Preprint at 10.1101/2020.04.03.024885 (2020).</mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Boorla, V. S., Chowdhury, R. &#x00026; Maranas, C. D. De novo design of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike protein. Preprint at 10.1101/2020.04.09.034868 (2020).</mixed-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Walter, J. D. et al. Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain. Preprint at 10.1101/2020.04.16.045419 (2020).</mixed-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><fpage>e1008421</fpage><?supplied-pmid 32407364?><pub-id pub-id-type="pmid">32407364</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>793</fpage><lpage>802</lpage><?supplied-pmid 32247326?><pub-id pub-id-type="pmid">32247326</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2801</fpage><lpage>2809</lpage><?supplied-pmid 12734147?><pub-id pub-id-type="pmid">12734147</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>507</fpage><lpage>513</lpage><?supplied-pmid 32007143?><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref></ref-list></back></article>